Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL
Zentalis Pharmaceuticals — Investor Presentation (May 2026)
29 slides from Zentalis Pharmaceuticals's investor presentation, May 12, 2026
Slide 1: Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care
Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care Corporate Presentation | May 2026 Nasdaq: ZNTL
Slide 2: Forward-Looking Statements
Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All stat
Slide 3: A Focused Strategy to Address Critical Unmet Need in Ovarian Cancer and Beyond
A Focused Strategy to Address Critical Unmet Need in Ovarian Cancer and Beyond Addressing ~21,500 Cyclin E1-positive PROC patients^ with no specifically targeted treatment options Abbreviations: PROC = platinum-resistant ovarian cancer ^ Based on 2024 annual estimates in US and EU4 (France, Germany,
Slide 4: Strong Execution Drives Momentum Towards Key Value Inflection Points
Strong Execution Drives Momentum Towards Key Value Inflection Points Abbreviations: PROC = platinum-resistant ovarian cancer; 5:2 schedule = 5 days once-daily administration of azenosertib, followed by 2 days without azenosertib4 Established solid clinical foundation for the lead indication in Cycli
Slide 5: ~50% of PROC Patients Are Cyclin E1-Positive With No Approved, Specifically Targeted Therapy
~50% of PROC Patients Are Cyclin E1-Positive With No Approved, Specifically Targeted Therapy 1. Cyclin E1-positive determined by an IHC assay and Zentalis proprietary cutoff 2. Based on 2024 annual estimates in US and EU4 (France, Germany, Italy, Spain) + UK 3. Eskander, R., et al. Front Oncol. 2023
Slide 6: Robust Clinical Foundation Supports Azenosertib as Potential Best-in-Class WEE1 Inhibitor
Robust Clinical Foundation Supports Azenosertib as Potential Best-in-Class WEE1 Inhibitor for Cyclin E1-Positive PROC Abbreviations: PROC = platinum-resistant ovarian cancer; TRAEs = treatment-related adverse events; 5:2 schedule = 5 days once-daily administration of azenosertib, followed by 2 days
Slide 7: DENALI: Registration-Intended Study in Cyclin E1-Positive PROC for Accelerated Approval
DENALI: Phase 2 Registration-Intended Study in Cyclin E1-Positive PROC for Accelerated Approval Abbreviations: 5:2 schedule = 5 days once-daily administration of azenosertib, followed by 2 days without azenosertib; IHC= immunohistochemistry; MIRV=mirvetuximab soravtansine; PROC=platinum resistant ov
Slide 8: ASPENOVA: Phase 3 Confirmatory Study in Cyclin E1-Positive PROC for Full Approval
ASPENOVA: Phase 3 Confirmatory Study in Cyclin E1-Positive PROC for Full Approval Abbreviations: 5:2 schedule = 5 days once-daily administration of azenosertib, followed by 2 days without azenosertib; IHC= immunohistochemistry; MIRV=mirvetuximab soravtansine; PROC=platinum resistant ovarian cancer;
Slide 9: Focused Pipeline with Registration-Intended Cyclin E1-Positive PROC Trials
Focused Pipeline with Registration-Intended Cyclin E1-Positive PROC Trials Abbreviations: PROC = platinum-resistant ovarian cancer; SOC = standard-of-care; 1L = first line; 2L = second line; PSOC = platinum-sensitive ovarian cancer * Also known as ZN-c3-002 9 Potential for Franchise Expansion in Ear
Slide 10: Cyclin E1-Positive PROC Patients Face Poor Prognosis with No Specifically Targeted Treatment Options
Cyclin E1-Positive PROC Patients Face Poor Prognosis with No Specifically Targeted Treatment Options Abbreviations: PROC = platinum-resistant ovarian cancer10
Slide 11: Cyclin E1 Protein Overexpression is the Key Biomarker Identifying PROC Patients
Cyclin E1 Protein Overexpression is the Key Biomarker Identifying PROC Patients Who may Benefit from Azenosertib Monotherapy Multiple mechanisms drive Cyclin E1 protein overexpression1, including: • CCNE1 gene amplification • Increased gene transcription • Reduced protein degradation *Cyclin E1 IHC+
Slide 12: Cyclin E1-Positive Patients Experience Significantly Worse Outcomes with Current Treatments
Cyclin E1-Positive Patients Experience Significantly Worse Outcomes with Current Treatments Abbreviations: mPFS = median progression-free survival; DCR = disease control rate; mTTNT = median time to next treatment; OC = ovarian cancer; PROC = platinum-resistant ovarian cancer; Tx = treatment; 1L = f
Slide 13: Standard-of-Care Single-Agent Chemotherapy Delivers Limited Benefits to PROC Patients
Standard-of-Care* Single-Agent Chemotherapy Delivers Limited Benefits to PROC Patients Direct cross-study comparison of results from independently conducted clinical trials is not intended on this slide. * Excludes recently approved taxane combo regimens Abbreviations: bev, bevacizumab; FRα, folate
Slide 14: Azenosertib May Address Critical Gap in Cyclin E1-Positive PROC Treatment Landscape
Azenosertib May Address Critical Gap in Cyclin E1-Positive PROC Treatment Landscape* *If successful in clinical testing and approved by regulators Abbreviations: PROC = platinum-resistant ovarian cancer; FRα = Folate Receptor alpha 1Jeong et al., AACR 2026, Poster #1708; 2 Excludes recently approved
Slide 15: Compelling Clinical Profile Across Multiple Studies Supports Cyclin E1-Positive PROC Registration Strategy
Compelling Clinical Profile Across Multiple Studies Supports Cyclin E1-Positive PROC Registration Strategy Abbreviations: PROC = platinum-resistant ovarian cancer 15
Slide 16: Azenosertib: A Differentiated, Potentially First-in-Class WEE1 Inhibitor
Azenosertib: A Differentiated, Potentially First-in-Class WEE1 Inhibitor 16 • Cyclin E1 overexpression increases CDK2 activity and accelerates G1-S transition, rendering cells more dependent on the DNA repair at the G2-M checkpoint • Inhibition of WEE1 activates CDKs, accelerates G1-S and G2-M trans
Slide 17: Integrated Data Across Multiple Early Clinical Studies Demonstrate Compelling Benefit-Risk Profile
Integrated Data Across Multiple Early Clinical Studies Demonstrate Compelling Benefit-Risk Profile for Azenosertib Monotherapy in PROC 800+ patients have been treated with azenosertib across all studies, including additional tumor types, monotherapy and combination therapies. This slide focuses on P
Slide 18: 400mg QD 5:2 Shows >30% ORR and ~6 Month Duration in Cyclin E1-Positive PROC
400mg QD 5:2 Shows >30% ORR and ~6 Month Duration in Cyclin E1-Positive PROC *Includes patients who received at least one post-treatment scan Abbreviations: CI = confidence interval; cPR = confirmed partial response; mDOR = median duration of response; PD = progressive disease; SD = stable disease;
Slide 19: Safety and Tolerability at 300mg and 400mg QD 5:2 Broadly Comparable
Safety and Tolerability at 300mg and 400mg QD 5:2 Broadly Comparable Data cutoff Dec 2, 2024. Active database; subject to further change. Neutropenia: Neutropenia, neutrophil count decreased, neutrophil percentage decreased; Thrombocytopenia: platelet count decreased and thrombocytopenia; Anemia: he
Slide 20: DENALI Part 1b Patient Characteristics: Heavily Pre-Treated PROC Population
DENALI Part 1b Patient Characteristics: Heavily Pre-Treated PROC Population Data cutoff date: January 13, 2025. aFull analysis set: all treated patients. Biomarker dataset: all treated patients with evaluable tissue and Cyclin E1 IHC status. bHispanic. c85% (23/27) of patients with CCNE1-amplified t
Slide 21: DENALI Part 1b Demonstrated Cyclin E1 as Predictive Biomarker for Response to Azenosertib
DENALI Part 1b Demonstrated Cyclin E1 as Predictive Biomarker for Response to Azenosertib Data cutoff date: Jan 13, 2025. aIntent to treat/Full analysis set: all treated patients. bBiomarker dataset: all treated patients with evaluable tissue and Cyclin E1 IHC status. cIncludes patients who received
Slide 22: Durable Responses Observed in Cyclin E1-Positive PROC Patients
Durable Responses Observed in Cyclin E1-Positive PROC Patients amDOR is subject to change, there are 4 ongoing responders as of the January 13, 2025 data cutoff. IHC, immunohistochemistry; cPR, confirmed partial response; SD, stable disease; PD, progressive disease; mDOR, median duration of response
Slide 23: DENALI Part 1b Safety and Tolerability Summary
DENALI Part 1b Safety and Tolerability Summary Data cutoff date: January 13, 2025 aIf a patient had multiple grades of the same adverse event, The worse grade was reported bOne patient had sepsis, and one patient had pancytopenia. ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRAE,
Slide 24: Building Azenosertib Franchise in Ovarian Cancer and Beyond
Building Azenosertib Franchise in Ovarian Cancer and Beyond 24
Slide 25: MUIR: Phase 1b Study of Azenosertib Combination Therapy in Ovarian Cancer
MUIR: Phase 1b Study of Azenosertib Combination Therapy in Ovarian Cancer Abbreviations: PROC = platinum-resistant ovarian cancer; 1L = first line; 2L = second line; PARPi = poly(ADP-ribose) polymerase inhibitor; ORR = overall response rate; DOR = duration of response; PFS = progression-free surviva
Slide 26: Azenosertib Combinations Demonstrate Compelling Activity in Preclinical ADC-Resistant TNBC Models
Azenosertib Combinations Demonstrate Compelling Activity in Preclinical ADC-Resistant Triple-Negative Breast Cancer Models Preclinical data presented at AACR 2026 (Lee et al., Poster #3902, April 20, 2026) Abbreviations: TNBC = triple-negative breast cancer; ADC = antibody-drug conjugate; EV = enfor
Slide 27: Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care
27 Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care for Patients with Cyclin E1-Positive Ovarian Cancer and Beyond
Slide 28: Our Mission: Unburdening Patients Through a More Convenient, Targeted Approach to Cancer Care
Our Mission: Unburdening Patients Through a More Convenient, Targeted Approach to Cancer Care *As of January 13, 2025 data cutoff in DENALI Part 1b; mDOR subject to change **Cash, cash equivalents and marketable securities as of 3/31/26 Abbreviations: PROC = platinum-resistant ovarian cancer; ORR =
Slide 29: Contact
Julie Eastland Haibo Wang Chief Executive Officer jeastland@zentalis.com Chief Business Officer hwang@zentalis.com Aron Feingold VP, IR and Corporate Communications afeingold@zentalis.com
Zentalis Pharmaceuticals — Investor Presentation (May 2026) on 6ix